Completed PHASE2 INTERVENTIONAL NCT00103298

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

A Phase II Trial of Isolated Hepatic Perfusion (IHP) and Systemic FOLFOX4 for Subjects With Metastatic Unresectable Colorectal Cancers of the Liver With ≥ 40% Hepatic Tumor Burden

Sponsor: National Cancer Institute (NCI)

Conditions Colorectal Cancer Metastatic Cancer

Interventions FOLFOX regimen fluorouracil isolated perfusion leucovorin calcium melphalan oxaliplatin

Updated 5 times since 2017 Last updated: Jun 18, 2013 Started: Dec 31, 2004 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00103298, this PHASE2 trial focuses on Colorectal Cancer and Metastatic Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 5 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States